{"nctId":"NCT00615433","briefTitle":"Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia","startDateStruct":{"date":"2008-01"},"conditions":["Schizophrenia"],"count":478,"armGroups":[{"label":"Lurasdione 40mg tablets","type":"EXPERIMENTAL","interventionNames":["Drug: Lurasidone 40 mg tablets"]},{"label":"120mg","type":"EXPERIMENTAL","interventionNames":["Drug: Lurasidone"]},{"label":"15mg Olz","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Olanzapine"]},{"label":"Sugar pill","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo comparator"]}],"interventions":[{"name":"Lurasidone","otherNames":[]},{"name":"Olanzapine","otherNames":[]},{"name":"Placebo comparator","otherNames":[]},{"name":"Lurasidone 40 mg tablets","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provide written informed consent and aged between 18 and 75 years of age.\n* Meets DSM-IV criteria for a primary diagnosis of schizophrenia.\n* Not pregnant, if of reproductive potential agrees to remain abstinent or use adequate and reliable contraception for duration of study.\n* Able and agrees to remain off prior antipsychotic medication for the duration of study.\n* Good physical health on the basis of medical history, physical examination, and laboratory screening.\n* Willing and able to comply with the protocol, including the inpatient requirements and outpatient visits.\n\nExclusion Criteria:\n\n* Considered by the investigator to be at imminent risk of suicide or injury to self, others or property.\n* Any chronic organic disease of the CNS (other than schizophrenia).\n* Used investigational compound within 30 days.\n* Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Total PANSS (Positive and Negative Syndrome Scale)Score From Baseline to the End of the Double Blind Treatment Period.","description":"The PANSS is a 30-item rating instrument evaluating the presence/absence and severity of positive, negative and general psychopathology of schizophrenia. The scale was developed from the BPRS and the Psychopathology Rating Scale. All 30 items are rated on a 7-point scale (1=absent; 7=extreme). The total score can range from 30 to 210. Lower scores represent less severity of illness.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.7","spread":null},{"groupId":"OG001","value":"-23.6","spread":null},{"groupId":"OG002","value":"-28.7","spread":null},{"groupId":"OG003","value":"-16.0","spread":null}]}]}]},{"type":"SECONDARY","title":"CGI-S (Clinical Global Impression - Severity) Change From Baseline to the End of the Double-blind Treatment.","description":"The CGI-S is a clinician-rated assessment of the subject's current illness state on a 7-point scale, where a higher score is associated with greater illness severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":null},{"groupId":"OG001","value":"-1.4","spread":null},{"groupId":"OG002","value":"-1.5","spread":null},{"groupId":"OG003","value":"-1.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":119},"commonTop":["Headache","Insomnia","Akathisia","Sedation","Somnolence"]}}}